Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: iNO administered Clear all
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study

NCT03911739
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opiate Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Jacksonville, Florida • Boston, Massachusetts • Portland, Oregon + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Recruiting Not applicable Interventional

Vascular ARDS Recruitment After Inhaled Nitric Oxide

NCT05801224
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Ventilation Perfusion Mismatch
Interventions
Nitric Oxide
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia

NCT03576885
View directory record Official record
Conditions
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions
inhaled nitric oxide, Placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
23 Weeks to 29 Weeks
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease

NCT00543933
View directory record Official record
Conditions
Pulmonary Insufficiency
Interventions
iNO administered
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection

NCT00000669
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 24, 2026, 4:27 AM EDT
Withdrawn Phase 2 Interventional

Effects of Nitric Oxide on the Endothelium During Hemolysis.

NCT03748082
View directory record Official record
Conditions
Endothelial Dysfunction, Hemolysis Intravascular, Cardiovascular Diseases, Cardiovascular Risk Factor
Interventions
Nitric Oxide, Reactive Hyperemia Index, Endothelial Cells Collection
Drug · Diagnostic Test · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Withdrawn Phase 2 Interventional

Effects of Prolonged Delivery of Nitric Oxide Gas on Plasma Reduction-Oxidation Reactions in Cardiac Surgical Patients

NCT04022161
View directory record Official record
Conditions
Cardiovascular Diseases, Oxidative Stress, Endothelial Dysfunction
Interventions
Nitrogen Gas for Inhalation, Blood withdrawal, Nitric Oxide
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 24, 2026, 4:27 AM EDT
Withdrawn Phase 2 Interventional

Effect of iNO in Patients With Submassive and Massive PE

NCT04996667
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Embolism Subacute Massive
Interventions
inhaled nitric oxide (iNO)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

NCT02288091
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts

NCT01172691
View directory record Official record
Conditions
Liver Transplant
Interventions
Inhaled Nitric Oxide (iNO), Placebo Arm (Nitrogen)
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
17 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)

NCT03168711
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Boston, Massachusetts • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement

NCT02674386
View directory record Official record
Conditions
Osteoarthritis
Interventions
Investigational Medical Product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex

NCT00000672
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
66
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Nitric Oxide for Inhalation During Left Ventricular Assists Device (LVAD) Implantation

NCT00060840
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nitric Oxide, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
8
States / cities
Newark, New Jersey • Durham, North Carolina • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

NCT00001122
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies

NCT03031938
View directory record Official record
Conditions
Osteoarthritis, Cancer Pain, Recurrent Low Back Pain
Interventions
Investigational medical product (IMP) administered in parent study
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 2 Months
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis

NCT00570349
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide for Inhalation, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional

A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex

NCT00000710
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

NCT00931632
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Inhaled Nitric Oxide, Placebo
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Days to 14 Days
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2017 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of INO-A002 in Healthy Dengue Virus-naive Adults

NCT03831503
View directory record Official record
Conditions
Healthy Volunteers
Interventions
INO-A002, CELLECTRA® 2000, Dengue Fever Antibodies (IgG)
Biological · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

NCT00795132
View directory record Official record
Conditions
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma
Interventions
Busulfan, Anti-Thymocyte Globulin, Fludarabine, Cyclosporine, Mycophenolate mofetil
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 21 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 24, 2026, 4:27 AM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 24, 2026, 4:27 AM EDT